Translating basic cancer biology into effective clinical therapies remains a major challenge due to differences in research models, communication gaps, and limited funding. This commentary underscores the transformative potential of international collaborations, which integrate diverse resources, multidisciplinary talent, and innovative trial designs to bridge the gap between laboratory discoveries and clinical applications. By fostering global alliances, sharing knowledge, and harmonizing regulatory and funding frameworks, we can accelerate breakthroughs in cancer treatment, improving patient outcomes worldwide.

Precision oncology is predicated on the availability of robust biomarkers deployed at scale at the point of care. Although simple in conception, precision oncology often fails in practice because of the limitations of current diagnostic platforms, the emergence of drug resistance, an incomplete understanding of cancer pathogenesis, and the host immune response. Here, we discuss using real-world data, including exceptional responder analyses, to identify biomarkers of therapy response and strategies for overcoming barriers to the broader adoption of precision-oncology paradigms.

The identification of novel targets together with technological advances is transforming our ability to effectively modulate the tumor microenvironment.

Approaches for profiling the spatial proteome in tissues are the basis of atlas-scale projects that are delivering on their promise for understanding biological complexity in health and disease.

Genetic immune escape (GIE) alterations pose a significant challenge in cancer by enabling tumors to evade immune detection. These alterations, which …

The neoantigen discovery pipeline NeoDisc incorporates mass spectrometry immunopeptidomics data.

The clinical implications of molecular heterogeneity in HER2-positive breast cancer remain to be explored. Here, the authors investigate the transcriptomic landscape of HER2-positive breast cancer pat...

Triple-negative breast cancer (TNBC) is a heterogenous disease with several molecular subtypes previously described. Here the authors perform a spatial transcriptomics analysis on a series of 92 patie...

Denkert et al. evaluate the longitudinal changes in tumor tissue of triple-negative breast cancer in a clinical trial cohort treated with neoadjuvant immunotherapy plus chemotherapy. The role of diffe...

Studying the evolution of cancer malignancy in space and time provides clues that are crucial for understanding how tumors develop, how they evade the immune ...